KALA BIO Secures $12.5 Million in Private Placement Funding
KALA BIO, Inc. (NASDAQ:KALA), a leading biopharmaceutical company focused on developing therapies for eye diseases, has announced a successful private placement agreement with institutional accredited investors. The company will be selling shares of its common stock and Series H Convertible Non-Redeemable Preferred Stock, generating approximately $12.5 million in gross proceeds.
This news comes in the wake of an increase in KALA BIO’s current liabilities in the first quarter of 2024, resulting in a decline in the company’s working capital ratio. Despite this, KALA BIO remains committed to advancing its research and development efforts for rare and severe eye diseases.
The private placement funding will provide KALA BIO with additional resources to continue its innovative work in the field of ophthalmology. With this financial support, the company aims to further its mission of delivering innovative therapies to patients in need.
Investors and industry experts are optimistic about KALA BIO’s future prospects, as the company continues to make strides in the development of cutting-edge treatments for eye conditions. This latest funding round will further solidify KALA BIO’s position as a key player in the biopharmaceutical landscape.
Comments